West Pharmaceutical Services R&D decreased by 27.5% to $15.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 3.1%, from $16.30M to $15.80M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 8.9% CAGR.
Analysis
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_developmentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.80M | $13.10M | $13.70M | $14.60M | $14.40M | $13.60M | $15.90M | $17.10M | $16.50M | $16.40M | $18.40M | $17.60M | $17.50M | $15.50M | $18.50M | $16.30M | $19.10M | $17.10M | $21.80M | $15.80M |
| QoQ Change | — | -5.1% | +4.6% | +6.6% | -1.4% | -5.6% | +16.9% | +7.5% | -3.5% | -0.6% | +12.2% | -4.3% | -0.6% | -11.4% | +19.4% | -11.9% | +17.2% | -10.5% | +27.5% | -27.5% |
| YoY Change | — | — | — | — | +4.3% | +3.8% | +16.1% | +17.1% | +14.6% | +20.6% | +15.7% | +2.9% | +6.1% | -5.5% | +0.5% | -7.4% | +9.1% | +10.3% | +17.8% | -3.1% |
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Proprietary Products | — | — | — | $16.30M | $19.10M | $17.10M | $21.80M | $15.80M |
| Contract-Manufactured Products | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| West Vantage | — | — | — | — | — | — | — | $0.00 |
| Total | $17.50M | $15.50M | $18.50M | $16.30M | $19.10M | $17.10M | $21.80M | $15.80M |
Contract-Manufactured Products was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
R&D at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's r&d?
- West Pharmaceutical Services (WST) reported r&d of $15.80M in Q1 2026.
- How has West Pharmaceutical Services's r&d changed year-over-year?
- West Pharmaceutical Services's r&d decreased by 3.1% year-over-year, from $16.30M to $15.80M.
- What is the long-term trend for West Pharmaceutical Services's r&d?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's r&d has grown at a 8.9% compound annual growth rate (CAGR), from $52.80M to $74.30M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.